Brought to you by 
BMS, Millennium in pharmacogenomics alliance
05 Oct 2000
Executive Summary
In a five-year collaboration, BMS will apply Millennium Predictive Medicine's cancer pharmacogenomics technology to its oncology drugs that are in development and to those that are already marketed. The alliance is the first to apply the technology to drugs that are in both stages.
Deal Industry
- Pharmaceuticals
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
-
Drug Discovery Tools
- Bioinformatics
- Genomics-Proteomics
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
BMS, Millennium in pharmacogenomics alliance
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice